About Budget Longevity Medicine

We explore the life extension strategies of lifestyle, supplements, repurposed medicines, peptides and regenerative health to help you achieve extraordinary lifespan goals beyond 150 years.

Our Mission

The Strategy: Outlast

Our goal is not to chase every headline. Our goal is to outlast the present.

To remain alive, alert, and resilient — long enough to ride the crest of the next great wave. That means building a regimen you can sustain. Not perfection, but persistence. Not hype, but habit.

Your tools are simple: Diet. Lifestyle. Medications. Supplements.

Your niche is your strategy. Your rhythm is your lifeline.

Some ideas in this book will be proven wrong. Others will evolve. But the principle remains: survival is strategy. The future belongs to those who prepare for it now.

"What is Longevity Escape velocity"?

Recent Information on Longevity

Confirmation of Our Approach to Budget Longevity

Rapamycin Update 2.8.26

Rapamycin Dosing for Longevity: What Emerging Human Research Reveals About How Dose and Timing Shape Autophagy Without Compromising Metabolic Health

WRITTEN BY

Dr. Richard LaFountain

Daniel Tawfik

PUBLISHED02 / 07 / 2026

Take Home Points

Rapamycin targets a conserved growth pathway repeatedly linked to aging. In multiple species, chronic mTORC1 overactivation drives age-related decline; rapamycin extends median and maximal lifespan in mice by ~15–36% depending on sex, strain, and timing of intervention.

Low-dose rapamycin for aging is typically discussed in the range of ~0.075–0.15 mg/kg once weekly, which corresponds roughly to 5–10 mg/week for a 70 kg adult, far below doses used in transplant medicine.

Much of what we know about dose–response for longevity comes from mice and dogs, especially the Dog Aging Project, where 0.15 mg/kg once weekly was chosen to balance meaningful mTOR inhibition with low risk of immunosuppression.

Early human studies show immune enhancement, not suppression, at low doses. In older adults, everolimus (0.5 mg/day or 5 mg weekly for 6 weeks) increased influenza vaccine response titers by ~20% and reduced PD-1–positive exhausted T cells, without increasing infection risk.

Body size, age, comorbidities, and drug interactions likely influence the “right” dose: mg/kg scaling, reduced kidney function, polypharmacy, and baseline immune status all change rapamycin exposure and risk.

Effective human dosing appears broader than initially assumed. Real-world and trial data suggest that weekly doses in the ~3–10 mg range can engage aging-related pathways, with circulating levels below those associated with transplant-level immunosuppression (>20 ng/mL).

Human longevity trials are still early—but signals are accumulating. While no trial has yet demonstrated lifespan extension in humans, early studies report improvements in immune function, cardiometabolic markers, muscle-related biomarkers, and patient-reported outcomes, supporting continued investigation of low-dose intermittent rapamycin.

Until larger, longer trials are complete, low-dose rapamycin for longevity remains experimental and should be framed as a research question not a finished clinical playbook.

Join Budget Longevity

Get expert tips on life extension and finance

Our Services

Explore lifestyle tips, supplements, and future medical advances to extend your healthy lifespan affordably.

Longevity Lifestyle

Practical lifestyle changes to support long-term health and extend your timespan effectively.

Future Medicine

Insights into regenerative treatments like stem cells and gene editing for life extension.